Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2011 Financial Results
Date:8/4/2011

in neurology.  The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine.  The U.S. Food and Drug Administration has accepted for filing the New Drug Application for LEVADEX for the potential acute treatment of migraine in adults. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the regulatory process to have the Company's LEVADEX product candidate approved for commercial use and the commercialization of LEVADEX, if approved. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, available at http://edgar.sec.gov.

'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
2. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
3. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
4. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
5. Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
6. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
7. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
9. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
10. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
11. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... ATLANTA, Nov. 28, 2011   CardioMEMS, Inc ., an ... commercializing a proprietary wireless sensing and communication technology for ... CEO, Jay Yadav, M.D. , has been recognized ... Endeavor Awards in the Technology Entrepreneur category. The awards ...
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
Cached Medicine Technology:TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 2TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 3PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2
(Date:4/15/2014)... mystery and in the process have found a potentially less ... million people a year. The researchers say they now understand the ... in use for more than 50 years even though it ... the microbes it attacks. , A report of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide insight ... issues in other areas of the world, which may have ... to successful interventions. , A report on the global ... to the HIV/AIDS pandemic, which has left 12 million children ...
(Date:4/14/2014)... shows that moderate to severe obstructive sleep apnea is independently associated ... of the 20-year follow-up study show that people with moderate to ... (hazard ratio = 4.2), nearly four times more likely to have ... from cancer (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... youth offenders, the answer to one open-ended question predicted the ... do you think you,ll live?", According to the study, having ... Dr. Alex Piquero said the study found those who don,t ... very high rates and commit more serious offenses, while those ...
(Date:4/14/2014)... fathers hard -- with symptoms increasing dramatically during some of ... Northwestern Medicine study has found. , Depressive symptoms increased on ... fatherhood for these young men, who were around 25 years ... same home as their children. The results of the study ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2
... Jan. 11 (HealthDay News) -- There is little evidence ... relieve the symptoms of osteoarthritis, according to a review ... that involves damage to cartilage and other structures in ... hips. It differs from rheumatoid arthritis, which is an ...
... of researchers at the California Institute of Technology (Caltech) ... The reaction they have come up with should enable ... of organic compounds called nitrogen-containing heterocycles, thus opening up ... natural products ranging from chemotherapeutic compounds to bioactive plant ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Jan. ... their heart race when they are having an irregular ... double their risk of stroke, a new study finds. ... not have a history of atrial fibrillation, more than ...
... During 2010-2011, University of Louisville Health Sciences Center faculty ... $5.7 million in the four regions of Kentucky served ... faculty from UofL provided donated services valued at $5,606,599 ... living and travel expenses in the four regions. These ...
... -- A genetic mutation that causes a rare immune ... been identified by scientists. Symptoms of the disorder ... (cold urticaria), according to the report published online in ... Journal of Medicine . The U.S. National Institutes ...
... HealthDay Reporter , WEDNESDAY, Jan. 11 (HealthDay News) -- ... type 1 diabetes appears to help re-educate rogue immune system ... insulin again. The treatment, which combines a patient,s ... blood, even worked in people with long-standing diabetes who were ...
Cached Medicine News:Health News:Herbal Medicines for Arthritis Not Backed by Evidence 2Health News:Herbal Medicines for Arthritis Not Backed by Evidence 3Health News:Caltech chemists devise chemical reaction that holds promise for new drug development 2Health News:Caltech chemists devise chemical reaction that holds promise for new drug development 3Health News:Even When Silent, Irregular Heartbeat Linked to Stroke Risk 2Health News:UofL centers have economic impact in excess of $5.7 million 2Health News:UofL centers have economic impact in excess of $5.7 million 3Health News:Gene Research Sheds Light on Rare Immune Disease 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 3
Inquire...
Sterilization: sterilized Yes...
Transparent film for easy visual monitoring of samples...
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
Medicine Products: